---
document_datetime: 2023-09-21 17:47:30
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/quixidar-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: quixidar-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2507158
conversion_datetime: 2025-12-25 06:00:01.041071
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
For procedures finalised before 01/11/2004, please refer to module 8A

## MAJOR CHANGES 1

| No      | Scope                                                                                                                                                                                                                                                                                   | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0033 | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                              | 20/09/2007          | 09/10/2007                               | SPC                              |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0032 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                        | 19/07/2007          | 03/09/2007                               | no longer SPC, PL                | Amendment of the posology (Section 4.2) for the prevention of venous thromboembolism (VTE) in patients with moderate renal impairment. Related changes are also proposed to Section 4.4 of the SPC and Sections 2 and 3 of the Package Leaflet. In addition, the MAHapplied for minor changes to Section 4.2, 5.1 and 9 of the SPC and to Section 6 of the Package Leaflet. The Package Leaflet has been updated accordingly. |
| X/0025  | 02_v_Change or addition of a new route of administration New intravenous use of the 2.5 mg strength to be administered as the first dose of fondaparinux in patients with STEMI eligible for treatment with fondaparinux (subsequent doses are administered by subcutaneous injection). | 21/06/2007          | Product 29/08/2007                       | SPC, Labelling, PL               | Please refer to the Scientific discussion: Quixidar-H-404-X-25 and II- 24.                                                                                                                                                                                                                                                                                                                                                    |
| II/0024 | Extension of Indication of the 2.5 mg strength to include a new indication in the treatment of Acute Coronary Syndromes as follows: Treatment of unstable angina or non-ST segment elevation myocardial infarction                                                                      | 21/06/2007          | 29/08/2007                               | SPC, Annex II, Labelling, PL     | Please refer to the Scientific discussion: Quixidar-H-404-II-24.                                                                                                                                                                                                                                                                                                                                                              |

<!-- image -->

Medicinal Product no longer authorised 1/3 Quixidar Procedural steps taken and scientific information after the authorisation Changes made after 01/11/2004

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                           | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | (UA/NSTEMI) in patients for whom urgent (<120mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1). Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy The new indication is based on the results of the OASIS-5 (UA/NSTEMI) and OASIS-6 (STEMI) trials. |                     |                                          | longer                           |                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0027  | Renewal of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                          | 22/02/2007          | 20/04/2007                               | no SPC, Annex II, Labelling, PL  | The CHMP reviewed the extensive data made available during the first 5 years after Marketing Authorisation and concluded that the efficacy of fondaparinux is well established in a number of life-threatening clinical settings and that the safety of fondaparinux is well known and documented in the SPC. The CHMP is of the opinion that the renewal can be granted with unlimited validity. |
| II/0012 | Extension of Indication. The MAHapplied for the addition of a new indication, namely \"Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1)\".                                                                                     | 26/05/2005          | Product 07/07/2005                       | SPC, PL                          | Please refer to the Scientific discussion: Quixidar-H-404-II-12.                                                                                                                                                                                                                                                                                                                                  |
| II/0010 | Extension of Indication. The MAHapplied for the addition of a new indication regarding `Prevention of VTE in medical patients who are at risk for thromboembolic complications due to restricted mobility during acute illness'.                                                                                                                                                                                | 15/12/2004          | 25/01/2005                               | SPC, PL                          | Please refer to the Scientific discussion: Quixidar-H-404-II-10.                                                                                                                                                                                                                                                                                                                                  |
| T/0014  | Transfer of Marketing Authorisation Holder                                                                                                                                                                                                                                                                                                                                                                      | 03/12/2004          | 12/01/2005                               | SPC, Annex II, Labelling, PL     | Transfer of MAHfrom NV Organon to GlaxoSmithKline.                                                                                                                                                                                                                                                                                                                                                |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## MINOR CHANGES 3

| No      | Scope                                                                                                                                                                | Product Information affected 2   | Date 4     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------|
| N/0034  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                     | PL                               | 24/10/2007 |
| IA/0031 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                      |                                  | 25/04/2007 |
| IB/0030 | 42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                              | SPC                              | 07/12/2006 |
| IA/0028 | 13_a_Change in test proc. for active substance - minor change                                                                                                        |                                  | 25/09/2006 |
| IA/0026 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                |                                  | 31/08/2006 |
| IA/0023 | 04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                      |                                  | 21/07/2006 |
| IB/0022 | 41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                | SPC, Labelling, PL               | 07/02/2006 |
| IA/0020 | 09_Deletion of manufacturing site                                                                                                                                    |                                  | 13/05/2005 |
| IB/0019 | 38_c_Change in test procedure of finished product - other changes                                                                                                    |                                  | 17/01/2005 |
| IB/0018 | 37_a_Change in the specification of the finished product - tightening of specification limits                                                                        |                                  | 17/01/2005 |
| IB/0017 | longer 10_Minor change in the manufacturing process of the active substance 12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening |                                  | 17/01/2005 |
| IA/0015 | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                       | SPC, Annex II, PL                | 01/12/2004 |

<!-- image -->

Medicinal Product no longer authorised 3/3